Holding(s) in Company

RNS : FOR IMMEDIATE RELEASE

9 JUNE 2016

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

TR1 NOTIFICATION OF MAJOR INTEREST BY AVIVA

 

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received a TR-1 by Aviva plc and its subsidiaries, ("Aviva") confirming changes to its direct and indirect interest level. Aviva's holding in ImmuPharma remains at a total of 11,285,180 Ordinary Shares which equates to a current position in the Company of 9.27%.

 

 

Full disclosure of the TR1 is shown below:

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii				Immupharma plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):	CHANGE IN NATURE : SHARES LOANED OUT				√
3. Full name of person(s) subject to the notification obligation: iii		Aviva plc & its subsidiaries
4. Full name of shareholder(s)  (if different from 3.):iv		Registered Holder:   BNY Norwich Union Nominees Limited         628,858*                                                                 Chase (GA Group) Nominees Limited          7,677,826*   State Street Nominees Limited                      1,413,511*   *denotes direct interest     Chase (GA Group) Nominees Limited             661,222   Chase Nominees Limited                        275,292   Vidacos Nominees Limited                                 528,471
5. Date of the transaction and date on which the threshold is crossed or reached: v		7 June 2016
6. Date on which issuer notified:		8 June 2016
7. Threshold(s) that is/are crossed or reached: vi, vii		8% to 7% Change at Direct Interest Level (Box 8a)

 

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction				Resulting situation after the triggering transaction
	Number of Shares		Number of Voting Rights		Number of shares	Number of voting rights		% of  voting rights x
					Direct	Direct xi	Indirect xii	Direct		Indirect
Ordinary Shares   GB0033711010	11,285,180		11,285,180		11,185,180	9,720,195	1,464,985	7.98%		1.21%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument		Expiration date xiii		Exercise/ Conversion Period xiv		Number of voting rights that may be acquired if the instrument is exercised/ converted.			% of voting rights
RIGHT TO RECALL LOANED SHARES		N/A		N/A		100,000*   * Direct Interest			0.08%

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument	Exercise price	Expiration date xvii	Exercise/ Conversion period xviii	Number of voting rights instrument refers to	% of voting rights xix, xx

 

 

 

Total (A+B+C)
Number of voting rights	Percentage of voting rights
11,285,180	9.27%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-   Aviva Investors Global Services Limited: ·      Aviva plc (Parent Company) ·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) ·      Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) ·      Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
10. Name of the proxy holder:		See Section 4
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:	Figures are based the revised total number of voting rights of 121,781,219 as per the recent Confirmation of EIS and VCT Qualifying Status and Issue of Equity announcement of 01 March 2016.
14. Contact name:	Neil Whittaker, Aviva plc
15. Contact telephone number:	01603 684420

 

 

 

 

 

 

-Ends-

For further information please contact:   ImmuPharma plc (www.immupharma.org) + 44 (0) 20 7152 4080 Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations Twitter: @immupharma           + 44 (0) 7721 413496       Panmure, Gordon & Co., NOMAD & Broker   +44 (0) 20 7886 2500 Fred Walsh, Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking